Last checked at 29 Jan 2019 09:38
29 January 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Total Voting Rights and Director and Significant Shareholdings
Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, confirms that the 25,000,000 Subscription Shares issued pursuant to the Subscription announced on 21 December 2018 were admitted to trading on AIM ("Admission") on 28 January 2019.
The Company's issued share capital now consists of 194,566,092 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 194,566,092. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Directors' and Significant Shareholdings
Set out below are details of the Directors' beneficial shareholdings and, in so far as the Company has been made aware, shareholdings of certain new Significant shareholders following Admission, being DNCA Investments and Barrymore Investments Ltd.
Shareholder | Number of Shares | % of issued share capital |
Liquid Harmony Limited | 45,000,000 | 23.13% |
DNCA Investments | 12,000,000 | 6.17% |
Barrymore Investments Ltd* | 7,905,721 | 4.06% |
Mr Michael S Bradfield (Non-executive Director) | 7,080,740 | 3.64% |
Dr Michael Sinclair & Family (Chairman) | 6,594,660 | 3.39% |
AB Segulah** | 6,488,789 | 3.34% |
Dr P N Plowman (Non-executive Director) | 3,930,304 | 2.02% |
Dr Enrico C Vanni (Non-executive Director) | 1,926,361 | 0.99% |
Mr Nicolas Serandour (Chief Executive Officer) | 1,760,467 | 0.90% |
Professor Stephen Myers (Non-executive Director) | 783,902 | 0.40% |
Mr Hans Van Celsing (Non-executive Director) | 30,000 | 0.02% |
*Barrymore Investments Ltd is a company under the control of Seamus Mulligan.
**Gabriel Urwitz (Non-executive Director) is a director of AB Segulah
Defined terms in this announcement shall have the same meaning as in the announcement of 21 December 2018 unless otherwise defined herein.
Advanced Oncotherapy Plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 20 3617 8728 |
Nicolas Serandour, CEO | |
Stockdale Securities (Nomad & Joint Broker) | |
Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
Stifel Nicolaus Europe (Joint Broker) | |
Jonathan Senior | Tel: +44 20 7710 7600 |
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
Paul McManus / Anna Dunphy | Mob: +44 7980 54 1 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.